Optie A:
Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
Optie B:
Deel de link per e-mail
Link delen

vorige artikel Response shift effect on gastrointestinal quali...

volgende artikel Associations between living arrangements and he...

Tip

Swipe om te navigeren naar een ander artikel

01-04-2011 | Uitgave 3/2011

Patient-reported outcomes in clinical trials of inhaled asthma medications: systematic review and research needs

Tijdschrift:: Quality of Life Research > Uitgave 3/2011

Auteurs:: Geoff K. Frampton, Jonathan Shepherd

Extra’s

» Toegang tot de volledige tekst krijgen

Abstract

Purpose

To assess the diversity, application, analysis and interpretation of patient-reported outcomes (PROs) in asthma clinical trials.

Methods

We critically appraised the use of asthma-specific PROs in 87 randomised controlled trials (RCTs) of inhaled asthma medications published during 1985–2006.

Results

A total of 79 RCTs reported PROs, of which 78 (99%) assessed symptom scores and seven (9%) assessed asthma quality of life scores. Only eight (10%) used validated instruments and five (6%) provided clinical interpretation of scores. Due to heterogeneity in the reporting of symptom measures, it is not possible to determine how many discrete symptom assessment instruments have been used. Only 26 (33%) of the RCTs that measured symptom scores reported the scores for follow-up. Limited improvement occurred over time: fewer than 30% of the RCTs used validated PRO measures in any individual year.

Conclusion

Numerous validated PRO instruments are available but it is unclear why few are used in asthma clinical trials. Problems include poor reporting, and uncritical analysis and interpretation of PRO scores. Research needs include identifying and recommending a set of PROs for use in asthma clinical research and providing guidance for researchers on the application, analysis and interpretation of PRO measures in clinical trials.

Log in om toegang te krijgen

Hier inloggen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Podotherapeut Totaal

Binnen de bundel kunt u gebruik maken van boeken, tijdschriften, e-learnings, web-tv's en uitlegvideo's. BSL Podotherapeut Totaal is overal toegankelijk; via uw PC, tablet of smartphone.

Meer informatie

(PDF 265 kb)

11136_2010_9750_MOESM1_ESM.pdf

(PDF 641 kb)

11136_2010_9750_MOESM2_ESM.pdf

Rosenzweig, J. R., Edwards, L., Lincourt, W., Dorinsky, P., & ZuWallack, R. L. (2004). The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma. Respiratory Medicine,98(12), 1157–1165.

Jenkins, C. R., Thien, F. C. K., Wheatley, J. R., & Reddel, H. K. (2005). Traditional and patient-centred outcomes with three classes of asthma medication. European Respiratory Journal,26(1), 36–44. PubMed

Atherton, H. A., White, P. T., Hewett, G., & Howells, K. (1996). Relationship of daytime asthma symptom frequency to morning peak expiratory flow. European Respiratory Journal,9(2), 232–236. PubMed

Brand, P. L. P., Duiverman, E. J., Postma, D. S., Waalkens, H. J., Kerrebijn, K. F., & van Essen-Zandvliet, E. E. M. (1997). Peak flow variation in childhood asthma: Relationship to symptoms, atopy, airways obstruction and hyperresponsiveness. European Respiratory Journal,10(6), 1242–1247. PubMed

Brand, P. L. P., Duiverman, E. J., Waalkens, H. J., van Essen-Zandvliet, E. E. M., & Kerrebijn, K. F. (1999). Peak flow variation in childhood asthma: Correlation with symptoms, airways obstruction, and hyperresponsiveness during long term treatment with inhaled corticosteroids. Thorax,54(2), 103–107. PubMed

Ståhl, E. (2000). Correlation between objective measures of airway calibre and clinical symptoms in asthma: A systematic review of clinical studies. Respiratory Medicine,94(8), 735–741. PubMed

Leone, F. T., Mauger, E. A., Peters, S. P., Chinchilli, V. M., Fish, J. E., Boushey, H. A., et al. (2001). The utility of peak flow, symptom scores, and β-agonist use as outcome measures in asthma clinical research. Chest,119(4), 1027–1033. PubMed

Kuntz, K. M., Kitch, B. T., Fuhlbrigge, A. L., Paltiel, A. D., & Weiss, S. T. (2002). A novel approach to defining the relationship between lung function and symptom status in asthma. Journal of Clinical Epidemiology,55(1), 11–18. PubMed

Mitra, A. D., Ogston, S., Crighton, A., & Mukhopadhyay, S. (2002). Lung function and asthma symptoms in children: Relationships and response to treatment. Acta Paediatrica,91(7), 789–792. PubMed

10.

Aburuz, S., McElnay, J., Gamble, M., Millership, J., & Heaney, L. (2005). Relationship between lung function and asthma symptoms in patients with difficult to control asthma. Journal of Asthma,42(10), 859–864. PubMed

11.

Wildhaber, J. H., Sznitman, J., Harpes, P., Straub, D., Möller, A., Basek, P., et al. (2007). Correlation of spirometry and symptom scores in childhood asthma and the usefulness of curvature assessment in expiratory flow-volume curves. Respiratory Care,52(12), 1744–1752. PubMed

12.

Juniper, E. F., Wisniewski, M. E., Cox, F. M., Emmett, A. H., Nielsen, K. E., & O’Byrne, P. M. (2004). Relationship between quality of life and clinical status in asthma: A factor analysis. European Respiratory Journal,23(2), 287–291. PubMed

13.

Strunk, R. C., & Korenblat, P. E. (2002). Choice of medication to treat asthma: Is an improvement in symptoms sufficient for deciding? Journal of Allergy and Clinical Immunology,110(6), 832–833. PubMed

14.

Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., Casale, T. B., et al. (2008). A new perspective on concepts of asthma severity and control. European Respiratory Journal,32(3), 545–554. PubMed

15.

Gill, T. M., & Feinstein, R. (1994). A critical appraisal of the quality of quality-of-life measurements. JAMA,272(8), 619–626. PubMed

16.

European Medicines Agency (EMEA). (2004). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. London: EMEA Committee for Medicinal Products for Human Use (CHMP). Report number EMEA/CHMP/EWP/139391/2004.

17.

Hays, R. D., & Hadorn, D. (1992). Responsiveness to change: An aspect of validity, not a separate dimension. Quality of Life Research,1(1), 73–75. PubMed

18.

Fitzpatrick, R., Davey, C., Buxton, M. J., & Jones, D. R. (1998). Evaluating patient-based outcome measures for use in clinical trials. Health Technology Assessment,2(14), 1–74. PubMed

19.

Juniper, E. F. (1998). Quality of life questionnaires: Does statistically significant = clinically important? Journal of Allergy and Clinical Immunology,102(1), 16–17. PubMed

20.

Wang, S. T., Yu, M. L., Wang, C. J., & Huang, C. C. (1999). Bridging the gap between the pros and cons in treating ordinal scales as interval scales from an analysis point of view. Nursing Research,48(4), 226–229. PubMed

21.

Kampen, J., & Swyngedouw, M. (2000). The ordinal controversy revisited. Quality & Quantity,34(1), 87–102.

22.

Jamieson, S. (2004). Likert scales: How to (ab)use them. Medical Education,38(12), 1212–1218.

23.

Kahler, E., Rogausch, A., Brunner, E., & Himmel, W. (2008). A parametric analysis of ordinal quality-of-life data can lead to erroneous results. Journal of Clinical Epidemiology,61(5), 475–480. PubMed

24.

Shepherd, J., Rogers, G., Anderson, R., Main, C., Thompson Coon, J., Hartwell, D., et al. (2008). Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta-2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health Technology Assessment,12(20), 1–274. PubMed

25.

Main, C., Shepherd, J., Anderson, R., Rogers, G., Thompson Coon, J., Liu, Z., et al. (2008). Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta-2 agonists for the treatment of chronic asthma in children under the age of 12 years. Health Technology Assessment,12(19), 1–192. PubMed

26.

National Institute for Health and Clinical Excellence (NICE). (2008). Corticosteroids for the treatment of chronic asthma in adults and children aged 12 years and over. NICE Technology Appraisal Report 138. London: National Institute for Health and Clinical Excellence. http://www.nice.org.uk/TA138 (Accessed July 2010).

27.

National Institute for Health and Clinical Excellence (NICE). (2007). Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years. NICE Technology Appraisal Report 131. London: National Institute for Health and Clinical Excellence. http://www.nice.org.uk/TA131 (Accessed July 2010).

28.

Frampton, G. K., Shepherd, J., & Dorne, J. L. C. M. (2009). Demographic data in asthma clinical trials: a systematic review with implications for generalizing trial findings and tackling health disparities. Social Science and Medicine,69(8), 1147–1154. PubMed

29.

Jarjour, N. N. (1999). Circadian variation in allergen and non-specific bronchial responsiveness in asthma. Chronobiology International,16(5), 631–639. PubMed

30.

Brennan, R. L., & Prediger, D. J. (1981). Coefficient kappa: Some uses, misuses, and alternatives. Educational and Psychological Measurement,41(3), 687–699.

31.

Emery, M.-P., Perrier, L.-L., & Acquadro, C. (2005). Patient-reported outcome and quality of life instruments database (PROQOLID): Frequently asked questions. Health and Quality of Life Outcomes, 3:12 (6 pp). (details of instruments at www.proqolid.org) (Accessed July 2010).

32.

American Thoracic Society Quality of Life Resource. http://qol.thoracic.org/sections/instruments/index.html (Accessed July 2010).

33.

Rafferty, P., Tucker, L. G., & Frame, M. H. (1985). Comparison of budesonide and beclomethasone dipropionate in patients with severe chronic asthma: Assessment of relative prednisolone-sparing effects. British Journal of Diseases of the Chest,79(3), 244–250. PubMed

34.

Ebden, P., Jenkins, A., Houston, G., & Davies, B. H. (1986). Comparison of two high dose corticosteroid aerosol treatments, beclomethasone dipropionate (1500 mug/day) and budesonide (1600 mug/day), for chronic asthma. Thorax,41(11), 869–874. PubMed

35.

Bisgaard, H., Nielsen, M. D., Andersen, B., Andersen, P., Foged, N., Fuglsang, G., et al. (1988). Adrenal function in children with bronchial asthma treated with beclomethasone dipropionate or budesonide. Journal of Allergy and Clinical Immunology,81(6), 1088–1095. PubMed

36.

Pedersen, S., & Fuglsang, G. (1988). Urine cortisol excretion in children treated with high doses of inhaled corticosteroids: A comparison of budesonide and beclomethasone. European Respiratory Journal,1(5), 433–435. PubMed

37.

Fitzgerald, D., Van Asperen, P., Mellis, C., Honner, M., Smith, L., & Ambler, G. (1998). Fluticasone propionate 750 μg/day versus beclomethasone dipropionate 1500 mug/day: Comparison of efficacy and adrenal function in paediatric asthma. Thorax,53(8), 656–661. PubMed

38.

Fabbri, L., Burge, P. S., Croonenborgh, L., Warlies, F., Weeke, B., Ciaccia, A., et al. (1993). Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax,48(8), 817–823. PubMed

39.

Barnes, N. C., Marone, G., Di Maria, G. U., Visser, S., Utama, I., & Payne, S. L. (1993). A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. European Respiratory Journal,6(6), 877–885. PubMed

40.

Lundback, B., Alexander, M., Day, J., Hebert, J., Holzer, R., et al. (1993). Evaluation of fluticasone propionate (500 μg day ^-1) administered either as dry powder via a Diskhaler(TM) inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 μg day ^-1) administered by pressurized inhaler. Respiratory Medicine,87(8), 609–620. PubMed

41.

Gustafsson, P., Tsanakas, J., Gold, M., Primhak, R., Radford, M., & Gillies, E. (1993). Comparison of the efficacy and safety of inhaled fluticasone propionate 200 μg/day with inhaled beclomethasone dipropionate 400 μg/day in mild and moderate asthma. Archives of Disease in Childhood,69(2), 206–211. PubMed

42.

Langdon, C. G., & Capsey, L. J. (1994). Fluticasone propionate and budesonide in adult asthmatics: A comparison using dry powder inhaler devices. British Journal of Clinical Research,5, 85–89.

43.

Langdon, C. G., & Thompson, J. (1994). A multicentre study to compare the efficacy and safety of inhaled fluticasone propionate and budesonide via metered-dose inhalers in adults with mild-to-moderate asthma. British Journal of Clinical Research,5, 73–84.

44.

Boe, J., Bakke, P., Rodolen, T., Skovlund, E., & Gulsvik, A. (1994). High-dose inhaled steroids in asthmatics: Moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. European Respiratory Journal,7(12), 2179–2184. PubMed

45.

Tjwa, M. K. T. (1995). Budesonide inhaled via Turbuhaler: A more effective treatment for asthma than beclomethasone dipropionate via Rotahaler. Annals of Allergy, Asthma & Immunology,75(2), 107–112.

46.

Connolly, A. (1995). A comparison of fluticasone propionate 100 μg twice daily with budesonide 200 μg twice daily via their respective powder devices in the treatment of mild asthma. A UK Study Group. European Journal of Clinical Research,7, 15–29.

47.

Bootsma, G. P., Dekhuijzen, P. N. R., Festen, J., Mulder, P. J. H., & van Herwaarden, C. L. A. (1995). Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma. Thorax,50(10), 1044–1050. PubMed

48.

Ayres, J. G., Bateman, E. D., Lundback, B., & Harris, T. A. J. (1995). High-dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. European Respiratory Journal,8(4), 579–586. PubMed

49.

Lorentzen, K. A., Van Helmond, J. L. M., Bauer, K., Langaker, K. E., Bonifazi, F., & Harris, T. A. J. (1996). Fluticasone propionate 1 mg daily and beclomethasone dipropionate 2 mg daily: A comparison over 1 yr. Respiratory Medicine,90(10), 609–617. PubMed

50.

Ringdal, N., Swinburn, P., Backman, R., Plaschke, P., Sips, A. P., Kjaersgaard, P., et al. (1996). A blinded comparison of fluticasone propionate with budesonide via powder devices in adult patients with moderate-to-severe asthma: A clinical evaluation. Mediators of Inflammation,5(5), 382–389. PubMed

51.

Hoekx, J. C., Hedlin, G., Pedersen, W., Sorva, R., Hollingworth, K., & Efthimiou, J. (1996). Fluticasone propionate compared with budesonide: A double-blind trial in asthmatic children using powder devices at a dosage of 400 micrograms day ^-1. European Respiratory Journal,9(11), 2263–2272. PubMed

52.

Basran, G., Campbell, M., Knox, A., Scott, R., Smith, R., Vernon, J., et al. (1997). An open study comparing equal doses of budesonide via Turbohaler with fluticasone propionate via Diskhaler in the treatment of adult asthmatic patients. European Journal of Clinical Research,9, 185–197.

53.

Agertoft, L., & Pedersen, S. (1997). A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler. Journal of Allergy and Clinical Immunology,99(6 I Suppl), 773–780. PubMed

54.

Yiallouros, P. K., Milner, A. D., Conway, E., & Honour, J. W. (1997). Adrenal function and high dose inhaled corticosteroids for asthma. Archives of Disease in Childhood,76(5), 405–410. PubMed

55.

Pauwels, R. A., Yernault, J. C., Demedts, M. G., & Geusens, P. (1998). Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. American Journal of Respiratory and Critical Care Medicine,157(3 I), 827–832. PubMed

56.

Bateman, E. D., Britton, M., Carrillo, J., Almeida, J., & Wixon, C. (1998). Salmeterol/fluticasone combination inhaler. A new, effective and well tolerated treatment for asthma. Clinical Drug Investigation,16(3), 193–201. PubMed

57.

Dal Negro, R., Micheletto, C., Tognella, S., Mauroner, L., Burti, E., Turco, P., et al. (1999). Effect of inhaled beclomethasone dipropionate and budesonide dry powder on pulmonary function and serum eosinophil cationic protein in adult asthmatics. Journal of Investigational Allergology and Clinical Immunology,9(4), 241–247. PubMed

58.

Raphael, G. D., Lanier, R. Q., Baker, J., Edwards, L., Rickard, K., & Lincourt, W. R. (1999). A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma. Journal of Allergy and Clinical Immunology,103(5 I), 796–803. PubMed

59.

Egan, J. J., Maden, C., Kalra, S., Adams, J. E., Eastell, R., & Woodcock, A. A. (1999). A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years. European Respiratory Journal,13(6), 1267–1275. PubMed

60.

Malo, J.-L., Cartier, A., Ghezzo, H., Mark, S., Brown, J., Laviolette, M., et al. (1999). Skin bruising, adrenal function and markers of bone metabolism in asthmatics using inhaled beclomethasone and fluticasone. European Respiratory Journal,13(5), 993–998. PubMed

61.

Heinig, J. H., Boulet, L. P., Croonenborghs, L., & Mollers, M. J. (1999). The effect of high-dose fluticasone propionate and budesonide on lung function and asthma exacerbations in patients with severe asthma. Respiratory Medicine,93(9), 613–620. PubMed

62.

Hughes, J. A., Conry, B. G., Male, S. M., & Eastell, R. (1999). One year prospective open study of the effect of high dose inhaled steroids, fluticasone propionate, and budesonide on bone markers and bone mineral density. Thorax,54(3), 223–229. PubMed

63.

Aubier, M., Pieters, W. R., Schlosser, N. J. J., & Steinmetz, K.-O. (1999). Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus(TM) inhaler (Seretide(TM)) is effective and safe in the treatment of steroid-dependent asthma. Respiratory Medicine,93(12), 876–884. PubMed

64.

Chapman, K. R., Ringdal, N., Backer, V., Palmqvist, M., Saarelainen, S., & Briggs, M. (1999). Salmeterol and fluticasone propionate (50/250 μg) administered via combination Diskus inhaler: As effective as when given via separate Diskus inhalers. Canadian Respiratory Journal,6(1), 45–51. PubMed

65.

Rao, R., Gregson, R. K., Jones, A. C., Miles, E. A., Campbell, M. J., & Warner, J. O. (1999). Systemic effects of inhaled corticosteroids on growth and bone turnover in childhood asthma: A comparison of fluticasone with beclomethasone. European Respiratory Journal,13(1), 87–94. PubMed

66.

Ferguson, A. C., Spier, S., Manjra, A., Versteegh, F. G. A., Mark, S., & Zhang, P. (1999). Efficacy and safety of high-dose inhaled steroids in children with asthma: A comparison of fluticasone propionate with budesonide. Journal of Pediatrics,134(4), 422–427. PubMed

67.

Jäger, L., Laurikainen, K., Leinonen, M., & Silvasti, M. (2000). Beclomethasone dipropionate Easyhaler(TM) is as effective as budesonide Turbohaler(TM) in the control of asthma and is preferred by patients. International Journal of Clinical Practice,54(6), 368–372. PubMed

68.

Medici, T. C., Grebski, E., Hacki, M., Ruegsegger, P., Maden, C., & Efthimiou, J. (2000). Effect of one year treatment with inhaled fluticasone propionate or beclomethasone dipropionate on bone density and bone metabolism: A randomised parallel group study in adult asthmatic subjects. Thorax,55(5), 375–382. PubMed

69.

Bousquet, J., D’Urzo, A., Hebert, J., Barraza, C. H., Boulet, L.-P., Suarez-Chacon, R., et al. (2000). Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler(TM). European Respiratory Journal,16(5), 808–816. PubMed

70.

Jenkins, C., Woolcock, A. J., Saarelainen, P., Lundbäck, B., & James, M. H. (2000). Salmeterol/fluticasone propionate combination therapy 50/250 μg twice daily is more effective than budesonide 800 μg twice daily in treating moderate to severe asthma. Respiratory Medicine,94(7), 715–723. PubMed

71.

Kavuru, M., Melamed, J., Gross, G., LaForce, C., House, K., Prillaman, B., et al. (2000). Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled trial. Journal of Allergy and Clinical Immunology,105(6 I), 1108–1116. PubMed

72.

Shapiro, G., Lumry, W., Wolfe, J., Given, J., White, M. V., Woodring, A., et al. (2000). Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma. American Journal of Respiratory and Critical Care Medicine,161(2 I), 527–534. PubMed

73.

Van den Berg, N. J., Ossip, M. S., Hederos, C. A., Anttila, H., Ribeiro, B. L., & Davies, P. I. (2000). Salmeterol/fluticasone propionate (50/100 μg) in combination in a Diskus ^(TM) inhaler (Seretide ^(TM)) is effective and safe in children with asthma. Pediatric Pulmonology,30(2), 97–105. PubMed

74.

O’Connor, B., Bonnaud, G., Haahtela, T., Luna, M. J., Querfurt, H., Wegener, T., et al. (2001). Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Annals of Allergy, Asthma & Immunology,86(4), 397–404.

75.

Aubier, M., Wettenger, R., & Gans, S. J. M. (2001). Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 μg day ^-1) versus HFA-fluticasone propionate (1000 μg day ^-1) in patients with asthma. Respiratory Medicine,95(3), 212–220. PubMed

76.

Johansson, G., McIvor, R. A., D’Ambrosio, F. P., Gratziou, C., & James, M. H. (2001). Comparison of salmeterol/fluticasone propionate combination with budesonide in patients with mild-to-moderate asthma. Clinical Drug Investigation,21(9), 633–642.

77.

Zetterström, O., Buhl, R., Mellem, H., Perpiñá, M., Hedman, J., O’Neill, S., et al. (2001). Improved asthma control with budesonide/formeterol in a single inhaler, compared with budesonide alone. European Respiratory Journal,18(2), 262–268. PubMed

78.

De Benedictis, F. M., Teper, A., Green, R. J., Boner, A. L., Williams, L., & Medley, H. (2001). Effects of 2 inhaled corticosteroids on growth: Results of a randomized controlled trial. Archives of Pediatrics and Adolescent Medicine,155(11), 1248–1254. PubMed

79.

Szefler, S. J., Martin, R. J., King, T. S., Boushey, H. A., Cherniack, R. M., Chinchilli, V. M., et al. (2002). Significant variability in response to inhaled corticosteroids for persistent asthma. Journal of Allergy and Clinical Immunology,109(3), 410–418. PubMed

80.

Ige, O. M., & Sogaolu, O. M. (2002). The clinical efficacy of fluticasone propionate (Fluvent) compared with beclomethasone dipropionate (Becotide) in patients with mild to moderate bronchial asthma at the University College Hospital, Ibadan, Nigeria. West African Journal of Medicine,21(4), 297–301. PubMed

81.

Ringdal, N., Chuchalin, A., Chovan, L., Tudoric, N., Maggi, E., Whitehead, P. J., et al. (2002). Evaluation of different inhaled combination therapies (EDICT): A randomised, double-blind comparison of Seretide (50/250 μg bd Diskus) vs. formoterol (12 μg bd) and budesonide (800 μg bd) given concurrently (both via Turbuhaler) in patients with moderate-to-severe asthma. Respiratory Medicine,96(11), 851–861. PubMed

82.

Rosenhall, L., Heinig, J. H., Lindqvist, A., Leegaard, J., Stahl, E., & Bergqvist, P. B. F. (2002). Budesonide/formoterol (symbicort) is well tolerated and effective in patients with moderate persistent asthma. International Journal of Clinical Practice,56(6), 427–433. PubMed

83.

Kannisto, S., Voutilainen, R., Remes, K., & Korppi, M. (2002). Efficacy and safety of inhaled steroid and cromone treatment in school-age children: A randomized pragmatic pilot study. Pediatric Allergy & Immunology,13(1), 24–30.

84.

Kannisto, S., Korppi, M., Remes, K., & Voutilainen, R. (2000). Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids. Journal of Clinical Endocrinology and Metabolism,85(2), 652–657. PubMed

85.

Tal, A., Simon, G., Vermeulen, J. H., Petru, V., Cobos, N., Everard, M. L., et al. (2002). Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatric Pulmonology,34(5), 342–350. PubMed

86.

Corren, J., Berkowitz, R., Murray, J. J., & Prenner, B. (2003). Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. International Journal of Clinical Practice,57(7), 567–572. PubMed

87.

Kuna, P. (2003). A randomized, double-blind, double-dummy, parallel-group, multicenter, dose-reduction trial of the minimal effective doses of budesonide and fluticasone dry-powder inhalers in adults with mild to moderate asthma. Clinical Therapeutics,25(8), 2182–2197. PubMed

88.

Busse, W., Koenig, S. M., Oppenheimer, J., Sahn, S. A., Yancey, S. W., Reilly, D., et al. (2003). Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 μg administered twice daily. Journal of Allergy and Clinical Immunology,111(1), 57–65. PubMed

89.

Bateman, E. D., Bantje, T. A., Gomes, M. J., Toumbis, M. G., Huber, R. M., & Naya, I. (2003). Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. American Journal of Respiratory Medicine,2(3), 275–281. PubMed

90.

Lalloo, U. G., Malolepszy, J., Kozma, D., Krofta, K., Ankerst, J., Johansen, B., et al. (2003). Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest,123(5), 1480–1487. PubMed

91.

Buhl, R., Creemers, J. P. H. M., Vondra, V., Martinelli, N. A., Naya, I. P., & Ekstrom, T. (2003). Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respiratory Medicine,97(4), 323–330. PubMed

92.

Parakh, U., Gupta, K., Sharma, S., & Gaur, N. (2004). A comparative evaluation of the efficacy of inhaled beclomethasone dipropionate, budesonide and fluticasone propionate in the management of bronchial asthma. Indian Journal of Allergy, Asthma and Immunology,18(1), 33–38.

93.

Prasad, R., Bandhu, M., Kant, S., Pandey, U., Ahuja, R., & Agarwal, G. (2004). A comparative study on efficacy of inhaled fluticasone propionate and beclomethasone dipropionate in patients of bronchial asthma. Indian Journal of Allergy, Asthma and Immunology,18(2), 73–77.

94.

Bergmann, K.-C., Lindemann, L., Braun, R., & Steinkamp, G. (2004). Salmeterol/fluticasone propionate (50/250 μg) combination is superior to double dose fluticasone (500 μg) for the treatment of symptomatic moderate asthma: A prospective, double-blind trial. Swiss Medical Weekly,134(3–4), 50–58. PubMed

95.

Zhong, N. S., Ping, Z. J., Humphries, M. J., & Xin, D. (2004). Salmeterol/fluticasone propionate in a single inhaler is superior to budesonide alone in control of Chinese asthmatic adults–An open-label, randomised, 6-week study. Clinical Drug Investigation,24(10), 583–592. PubMed

96.

Scicchitano, R., Aalbers, R., Ukena, D., Manjra, A., Fouquert, L., Centann, S., et al. (2004). Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion,20(9), 1403–1418. PubMed

97.

Bateman, E. D., Boushey, H. A., Bousquet, J., Busse, W. W., Clark, T. J. H., Pauwels, R. A., et al. (2004). Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. American Journal of Respiratory and Critical Care Medicine,170(8), 836–844. PubMed

98.

Aalbers, R., Backer, V., Kava, T. T. K., Omenaas, E. R., Sandstrom, T., Jorup, C., et al. (2004). Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Current Medical Research and Opinion,20(2), 225–240. PubMed

99.

Niphadkar, P., Jagannath, K., Joshi, J. M., Awad, N., Boss, H., Hellbardt, S., et al. (2005). Comparison of the efficacy of ciclesonide 160 μg QD and budesonide 200 μg BID in adults with persistent asthma: A phase III, randomized, double-dummy, open-label study. Clinical Therapeutics,27(11), 1752–1763. PubMed

100.

Kaur, C., Bansal, S. K., & Chhabra, S. K. (2005). Study on serum and urinary cortisol levels of asthmatic patients after treatment with high dose inhaled beclomethasone dipropionate or budesonide. Indian Journal of Chest Diseases and Allied Sciences,47(2), 89–95. PubMed

101.

Molimard, M., Martinat, Y., Rogeaux, Y., Moyse, D., Pello, J.-Y., & Giraud, V. (2005). Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide. Respiratory Medicine,99(6), 770–778. PubMed

102.

FitzGerald, J. M., Boulet, L.-P., & Follows, R. M. A. (2005). The CONCEPT trial: A 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clinical Therapeutics,27(4), 393–406. PubMed

103.

Vogelmeier, C., D’Urzo, A., Pauwels, R., Merino, J. M., Jaspal, M., Boutet, S., et al. (2005). Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option? European Respiratory Journal,26(5), 819–828. PubMed

104.

O’Byrne, P. M., Bisgaard, H., Godard, P. P., Pistolesi, M., Palmqvist, M., Zhu, Y., et al. (2005). Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine,171(2), 129–136. PubMed

105.

Altintas, D. U., Karakoc, G. B., Can, S., Yilmaz, M., & Kendirli, S. G. (2005). The effects of long term use of inhaled corticosteroids on linear growth, adrenal function and bone mineral density in children. Allergologia et Immunopathologia,33(4), 204–209. PubMed

106.

Malone, R., LaForce, C., Nimmagadda, S., Schoaf, L., House, K., Ellsworth, A., et al. (2005). The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Annals of Allergy, Asthma & Immunology,95(1), 66–71.

107.

Pohl, W. R., Vetter, N., Zwick, H., & Hrubos, W. (2006). Adjustable maintenance dosing with budesonide/formoterol or budesonide: Double-blind study. Respiratory Medicine,100(3), 551–560. PubMed

108.

Buhl, R., Vinkler, I., Magyar, P., Györi, Z., Rybacki, C., Middle, M. V., et al. (2006). Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulmonary Pharmacology and Therapeutics,19(6), 404–412. PubMed

109.

Koopmans, J. G., Lutter, R., Jansen, H. M., & van der Zee, J. S. (2006). Adding salmeterol to an inhaled corticosteroid: Long term effects on bronchial inflammation in asthma. Thorax,61(4), 306–312. PubMed

110.

Lundbäck, B., Rönmark, E., Lindberg, A., Jonsson, A.-C., Larsson, L.-G., Petavy, F., et al. (2006). Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respiratory Medicine,100(1), 2–10. PubMed

111.

Kuna, P., Creemers, J. P., Vondra, V., Black, P. N., Lindqvist, A., Nihlen, U., et al. (2006). Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma. Respiratory Medicine,100(12), 2151–2159. PubMed

112.

Nathan, R. A., Rooklin, A., Schoaf, L., Scott, C., Ellsworth, A., House, K., et al. (2006). Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: A randomized, double-blind, placebo-controlled, 12-week study. Clinical Therapeutics,28(1), 73–85. PubMed

113.

Dahl, R., Chuchalin, A., Gor, D., Yoxall, S., & Sharma, R. (2006). EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respiratory Medicine,100(7), 1152–1162. PubMed

114.

Jenkins, C., Kolarikova, R., Kuna, P., Caillaud, D., Sanchis, J., Popp, W., et al. (2006). Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology,11(3), 276–286. PubMed

115.

Bateman, E. D., Jacques, L., Goldfrad, C., Atienza, T., Mihaescu, T., & Duggan, M. (2006). Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. Journal of Allergy and Clinical Immunology,117(3), 563–570. PubMed

116.

Zietkowski, Z., Bodzenta-Lukaszyk, A., Tomasiak, M. M., Szymanski, W., & Skiepko, R. (2006). Effect of ciclesonide and fluticasone on exhaled nitric oxide in patients with mild allergic asthma. Respiratory Medicine,100(9), 1651–1656. PubMed

117.

Horiguchi, T., Hayashi, N., Ohira, D., Torigoe, H., Ito, T., Hirose, M., et al. (2006). Usefulness of HFA-BDP for adult patients with bronchial Asthma: Randomized crossover study with Fluticasone. Journal of Asthma,43(7), 509–512. PubMed

118.

Rabe, K. F., Pizzichini, E., Ställberg, B., Romero, S., Balanzat, A. M., Atienza, T., et al. (2006). Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma – A randomized, double-blind trial. Chest,129(2), 246–256. PubMed

119.

Jarjour, N. N., Wilson, S. J., Koenig, S. M., Laviolette, M., Moore, W. C., Davis, W. B., et al. (2006). Control of airway inflammation maintained at a lower steroid dose with 100/50 μg of fluticasone propionate/salmeterol. Journal of Allergy and Clinical Immunology,118(1), 44–52. PubMed

120.

Pohunek, P., Kuna, P., Jorup, C., & de Boeck, K. (2006). Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatric Allergy & Immunology,17(6), 458–465.

121.

Eisner, C., & Morse, R. (2001). Quality-of-life measures in chronic diseases of childhood. Health Technology Assessment,5(4), 1–148.

122.

Santanello, N. C., Barber, B. L., Reiss, T. F., Friedman, B. S., Juniper, E. F., & Zhang, J. (1997). Measurement characteristics of two asthma symptom diary scales for use in clinical trials. European Respiratory Journal,10(3), 646–651. PubMed

123.

Juniper, E. F., Guyatt, G. H., Epstein, R. S., Ferrie, P. J., Jaeschke, R., & Hiller, T. K. (1992). Evaluation of impairment of health related quality of life in asthma: Development of a questionnaire for use in clinical trials. Thorax,47(2), 76–83. PubMed

124.

Juniper, E. F., Guyatt, G. H., Feeny, D. H., Ferrie, P. J., Griffith, L. E., & Townsend, M. (1996). Measuring quality of life in children with asthma. Quality of Life Research,5(1), 35–46. PubMed

125.

Juniper, E. F., Guyatt, G. H., Cox, F. M., Ferrie, P. J., & King, D. R. (1999). Development and validation of the Mini Asthma Quality of Life Questionnaire. European Respiratory Journal,14(1), 32–38. PubMed

126.

Hyland, M. E. (1991). The living with asthma questionnaire. Respiratory Medicine,85(Supp B), 13–16. PubMed

127.

Ware, J. E., Kemp, J. P., Buchner, D. A., Singer, A. E., Nolop, K. B., & Goss, T. F. (1998). The responsiveness of disease-specific and generic health measures to changes in the severity of asthma among adults. Quality of Life Research,7(3), 235–244. PubMed

128.

Put, C., Demedts, M., van den Bergh, O., Demyttenaere, K., & Verleden, G. (1999). Asthma symptoms: Influence of personality versus clinical status. European Respiratory Journal,13(4), 751–756. PubMed

129.

Rietveld, S., & Prins, P. J. M. (1998). The relationship between negative emotions and acute subjective and objective symptoms of childhood asthma. Psychological Medicine,28(2), 407–415. PubMed

130.

Efficace, F., Bottomley, A., Osoba, D., Gotay, C., Flechtner, H., D’haese, S., et al. (2003). Beyond the development of health-related quality-of-life (HRQOL) measures: A checklist for evaluating HRQOL outcomes in cancer clinical trials – does HRQOL evaluation in prostate cancer research inform clinical decision making? Journal of Clinical Oncology,21(18), 3502–3511. PubMed

Titel: Patient-reported outcomes in clinical trials of inhaled asthma medications: systematic review and research needs
Auteurs:: Geoff K. Frampton
Jonathan Shepherd
Publicatiedatum: 01-04-2011
DOI: https://doi.org/10.1007/s11136-010-9750-1
Uitgeverij: Springer Netherlands
Tijdschrift: Quality of Life Research An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation - Official Journal of the International Society of Quality of Life Research
Uitgave 3/2011
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Tip

Swipe om te navigeren naar een ander artikel

Abstract

Purpose

Methods

Results

Conclusion

Log in om toegang te krijgen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Podotherapeut Totaal

Andere artikelen Uitgave 3/2011

Comparison of self-reported health-related quality of life between Taiwan hemodialysis and peritoneal dialysis patients: a multi-center collaborative study

Response shift effect on gastrointestinal quality of life index after laparoscopic cholecystectomy

Assessing longitudinal quality of life in prostate cancer patients and their spouses: a multilevel modeling approach

Translation of the Social Difficulties Inventory (SDI-21) into three south Asian languages and preliminary evaluation of SDI-21(Urdu)

Living with chronic pain

Using Rasch analysis to form plausible health states amenable to valuation: the development of CORE-6D from a measure of common mental health problems (CORE-OM)